Difficulty: Medium
Average Score: 68%
Practice
A 10-mo-old boy has a left suprarenal mass. Surgery is accomplished with complete removal of the mass as well as the non-adherent lymph nodes; surgical biopsies are taken during surgery. The histology reveals poorly differentiated neuroblastoma with microscopic ipsilateral lymph nodes involvement. The contralateral lymph nodes are negative. Of the following, the BEST therapeutic approach for this infant is
Correct answer
A
Rationale
In the case of a 10-month-old boy with a poorly differentiated neuroblastoma and microscopic ipsilateral lymph node involvement, the BEST therapeutic approach is chemotherapy (Option A).
The rationale behind this choice lies in the fact that neuroblastoma is a highly chemo-sensitive tumor in children. Chemotherapy is the preferred initial treatment as it can target cancer cells throughout the body, including those that may have spread beyond the primary tumor site. In this case, the microscopic lymph node involvement indicates the potential for spread, making systemic treatment like chemotherapy crucial.
The other options are suboptimal for several reasons:
- Radiotherapy (Option B) is generally avoided in young children due to the potential for long-term side effects on developing organs and tissues.
- Concomitant chemo-radiotherapy (Option C) may be too aggressive for an infant and is not the standard of care for this type of cancer in this age group.
- Chemotherapy followed by radiotherapy (Option D) is not recommended as upfront chemotherapy is the preferred initial treatment for neuroblastoma to target systemic disease.
In an educational context, understanding the rationale behind treatment choices in pediatric oncology is crucial for nurses caring for pediatric cancer patients. It is essential to prioritize treatments that offer the best chance of cure while minimizing long-term side effects, especially in young patients where organ development is ongoing. This question highlights the importance of tailoring treatment plans to the specific characteristics of pediatric cancers to optimize outcomes.
The rationale behind this choice lies in the fact that neuroblastoma is a highly chemo-sensitive tumor in children. Chemotherapy is the preferred initial treatment as it can target cancer cells throughout the body, including those that may have spread beyond the primary tumor site. In this case, the microscopic lymph node involvement indicates the potential for spread, making systemic treatment like chemotherapy crucial.
The other options are suboptimal for several reasons:
- Radiotherapy (Option B) is generally avoided in young children due to the potential for long-term side effects on developing organs and tissues.
- Concomitant chemo-radiotherapy (Option C) may be too aggressive for an infant and is not the standard of care for this type of cancer in this age group.
- Chemotherapy followed by radiotherapy (Option D) is not recommended as upfront chemotherapy is the preferred initial treatment for neuroblastoma to target systemic disease.
In an educational context, understanding the rationale behind treatment choices in pediatric oncology is crucial for nurses caring for pediatric cancer patients. It is essential to prioritize treatments that offer the best chance of cure while minimizing long-term side effects, especially in young patients where organ development is ongoing. This question highlights the importance of tailoring treatment plans to the specific characteristics of pediatric cancers to optimize outcomes.